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Open access undThe ﬂavonolignan silibinin, which is a mixture of two diastereoisomers, silybin A and silybin B, is a com-
ponent of the extract obtained from the fruit and seeds of the variegated milk thistle (Silybum marianum
(L.) Gaertn. (Asteraceae)), known as silymarin. Among the therapeutic properties credited to silibinin, its
antihyperglycaemic action has been extensively explored. Silibinin is structurally related to the ﬂavo-
noids quercetin and ﬁsetin, which have been previously demonstrated to be very active on liver meta-
bolic processes related to glycaemic regulation. The aim of the present work was to investigate the
effects of silibinin on metabolic pathways responsible for the maintenance of glycaemia, particularly gly-
cogenolysis and gluconeogenesis, in the perfused rat liver. The activities of some key enzymes in these
pathways and on parameters of energy metabolism in isolated mitochondria were also examined. At a
concentration range of 50–300 lM, silibinin inhibited gluconeogenesis in the fasted condition and inhib-
ited glycogenolysis and glycolysis in the fed condition. The mechanisms by which silibinin exerted these
actions were multiple and complex. It inhibited the activity of glucose 6-phosphatase, inhibited the pyru-
vate carrier, and reduced the efﬁciency of mitochondrial energy transduction. It can also act by reducing
the supply of NADH for gluconeogenesis and mitochondria through its pro-oxidative actions. In general,
the effects and the potency of silibinin were similar to those of quercetin and ﬁsetin. However, silibinin
exerted some distinct effects such as the inhibitory effect on oxygen consumption in the fed condition
and a change in the energy status of the perfused livers. It can be concluded that the effects of silibinin
on liver glucose metabolism may explain its antihyperglycaemic property. However, this effect was, in
part, secondary to impairment in cellular energy metabolism, a ﬁnding that should be considered in its
therapeutic usage.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
The ﬂavonolignan silibinin is a 1:1 mixture of two diastereoiso-
meric compounds, silybin A and silybin B (Fig. 1). Silibinin is a
semipuriﬁed, commercially available fraction of silymarin that is
extracted from the fruit and seeds of the variegated milk thistle
(Silybum marianum (L.) Gaertn. (Asteraceae)). Silymarin is a stand-
ardised extract composed of at least seven ﬂavonolignans (silybin
A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin,
and silydianin) and one ﬂavonoid (taxifolin) that comprise
65–80% of milk thistle extract. The two diastereoisomers that com-
prise the semipuriﬁed mixture, silibinin, are the most abundant.
(C.P. Colturato), rrconstantin
A.S. Maeda Jr.), rereconstantin
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er the Elsevier OA license.compounds in silymarin, but not the unique compounds that pres-
ent biological activities [1].
The most extensively studied and disseminated property of
silymarin is its hepatoprotective activity [2–6]. Several clinical
studies have been performed to evaluate the efﬁcacy of silyma-
rin/silibinin to treat a range of liver and gallbladder disorders such
as acute and chronic hepatitis, cirrhosis and toxin-induced hepati-
tis. Doses ranging from 240 to 800 mg/day for a period between
7 days and 6 years have been employed [5]. For instance, patients
with chronic alcoholic liver disease who received an oral dose of
420 mg/day of silymarin for 6 months, had normalised serum lev-
els of transaminases, bilirubin and gamma glutamyl transferase
[7]. There is also a reported improvement in the liver histology of
patients with alcoholic cirrhosis who received oral doses of
140 mg silibinin three times a day for 4 years [5]. However, in an-
other study with patients presenting symptoms of acute clinical
hepatitis, treatment with 420 mg/day of silymarin for 4 weeks
was able to reduce the symptoms related to biliary retention,
including dark urine, jaundice and scleras icterus, but not modify
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Fig. 1. Chemical structures of silibinin (1,2), quercetin (3) and ﬁsetin (4). Silibinin is a mixture of two diastereoisomers: silybin A(1) and silybin B(2). In the ﬁgures, the rings of
each compound are highlighted.
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tients with cirrhosis [8] receiving an oral dose of 600 mg/day of
silymarin, a decrease in fasting blood glucose and insulin levels
was observed after 4 months of treatment.
The cellular mechanisms by which silymarin and silibinin exert
their hepatoprotective effects have been suggested based on stud-
ies performed in cultures of hepatocytes and hepatomes or in ani-
mal experimental models [5]. They are believed to act as
antioxidant, anti-inﬂammatory and anti-ﬁbrotic agents. The anti-
inﬂammatory effect seems to involve blocking the activation of
intrahepatic Nuclear Factor kappa B (NF-kB), and consequent dim-
inution of Tumour Necrosis Factor-alpha (TNF-a), Interferon (IFN-
g), IL-2 and inducible Nitric Oxide Synthase (iNOS). The ability to
act as cellular antioxidants, on the other hand, has been attributed
to the many beneﬁcial effects of silymarin and silibinin. Haddad
et al. [9] for example, veriﬁed in an experimental model of NASH
(non-alcoholic steatohepatitis) that treatment with 200 mg/kg of
silibinin for 5 weeks caused an improvement of liver steatosis
and inﬂammation and decreased the levels of plasma insulin and
TNF-a. These effects were associated with decreased membrane li-
pid peroxidation, reduced free-radical release and restoration in
the GSH levels.
Besides hepatoprotection for many disorders, the property of
silymarin in reducing fasting glycaemia and insulin level have sup-
ported its use as an antihyperglycaemic compound [8,10–13]. A
commercial preparation of silibinin, Legalon, has been used in
the treatment of diabetic patients, and there is evidence that it pro-
motes a reduction in insulin resistance [8]. The potent hypoglycae-
mic and antihyperglycaemic activities of an aqueous extract of S.
marianum have also been demonstrated in experimental animal
models of diabetes [10,11].
Even so, the mechanisms by which silibinin exerts the antihy-
perglycaemic activity are not entirely understood. Besides a de-
crease in insulin resistance [8], there are suggestions that it may
reduce the mitochondrial ROS generation that is implicated in
the worsening of diabetes [13] and that it acts directly on liver
metabolic pathways, inhibiting the activity of key enzymes in glu-
coneogenesis and glycolysis [12]. Actually, inhibition of glucose 6-
phosphatase is an action shared among several other structurallyrelated phenolic compounds, including the ﬂavonoids quercetin
[14] and ﬁsetin [15].
We have already demonstrated that quercetin and ﬁsetin are
very active on liver metabolism, affecting several parameters that
modulate glycaemia. Both compounds inhibit gluconeogenesis in
livers from fasted rats. In livers from fed rats, quercetin stimulates
glycogenolysis and inhibits glycolysis. Fisetin, conversely, inhibits
glycogenolysis and glycolysis. Although, both quercetin and ﬁsetin
are very active on isolated mitochondria and affect various param-
eters of energy transduction [14–16], they do not cause signiﬁcant
changes in the concentrations of AMP, ADP and ATP in perfused liv-
ers. Another action common to both ﬂavonoids is a pro-oxidative
activity. They are able to oxidise NADH to shift the cellular condi-
tions to a more oxidised state [17].
It must be stressed that quercetin and ﬁsetin are classiﬁed as
ﬂavonoid compounds from the class of ﬂavonols while silibinin is
a ﬂavonolignan, which is a dimer of phenylpropanoid. As shown
in Fig. 1, ﬂavonoids are usually characterised by a carbon skeleton
C6–C3–C6. While the ﬁrst ring ‘‘A’’ is aromatic, the second ring ‘‘C’’ is
a heterocyclic ring attached to oxygen and connected via a C–C
bond to the third aromatic ring ‘‘B’’ [18]. The ﬂavonolignan silibinin
(mixture of silybin A and silybin B) has two additional rings, ‘‘D’’
and ‘‘E’’ (Fig. 1) [19]. Therefore, the question that arises is whether
the structural differences between silibinin, which is a ﬂavonolig-
nan, and quercetin and ﬁsetin, which are ﬂavonols, exert important
inﬂuences on their activities.
Given the therapeutic potential of silibinin and its current use
by human patients, it is highly desirable to more extensively char-
acterise its mode of action in biological systems. Thus, the present
work was planned to examine the effects of silibinin on liver met-
abolic pathways, particularly glycogenolysis and gluconeogenesis,
and its effects on related metabolic parameters, including the
activities of some key enzymes of these pathways and on parame-
ters of energy metabolism in isolated mitochondria. Besides the
elucidation of the role of the liver in the silibinin-induced changes
in glycaemia, this work will allow for a comparison of the effects of
silibinin with other structurally related phenolic compounds, quer-
cetin and ﬁsetin, and thus contribute to the understanding of this
class of natural substances with therapeutic properties. It must
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scribed as a simple compound, it is in fact the mixture of two dia-
stereoisomeric compounds, silybin A and silybin B.2. Material and methods
2.1. Materials
Silibinin that was purchased from Sigma Chemical Co. (St. Louis,
USA) is a mixture of two diastereoisomeric compounds (silybin A
and silybin B). All enzymes and coenzymes used in the enzymatic
assays were from Sigma Chemical Co. (St. Louis, USA). Sodium [14C]
bicarbonate (speciﬁc activity of 58 Ci/mmol) was purchased from
Amersham Pharmacia Biotech (Buckinghamshire, UK). All other
chemicals were of the best available grade.
2.2. Animals
Male Wistar rats weighing 180–220 g and fed ad libitum with a
standard laboratory diet (Nuvilab CR-1) were used in all experi-
ments. In some experimental protocols, the rats were fasted for
24 h before the surgical removal of the liver. All experiments were
performed in accordance with the internationally accepted recom-
mendations for the care and use of animals.
2.3. Liver perfusion
The liver perfusion apparatus was built in the workshops of the
University of Maringá. For the surgical procedure, the animals were
anaesthetised by an intraperitoneal injection of sodium pentobar-
bital (50 mg/kg). The haemoglobin-free, non-recirculating perfu-
sion was performed according to the technique described by
Scholz and Bücher [20]. After cannulation of the portal and cava
veins, the liver was positioned in a plexiglass chamber. Flow was
maintained constant by a peristaltic pump (Miniplus 3, Gilson,
France) and was adjusted to between 30 and 35 mL/min, depend-
ing on the liver weight. The perfusion ﬂuid was a Krebs/Hense-
leit-bicarbonate buffer (pH 7.4) that was saturated with a
mixture of oxygen and carbon dioxide (95:5) by means of a mem-
brane oxygenator with a simultaneous temperature adjustment for
37 C. The composition of the Krebs/Henseleit-bicarbonate buffer
is the following: 115 mM NaCl, 25 mM NaHCO3, 5.8 mM KCl,
1.2 mM Na2SO4, 1.18 mM MgCl2, 1.2 mM NaH2PO4, and 2.5 mM
CaCl2. Livers from rats that were fasted for 24 h were used in the
measurements for gluconeogenesis, and the livers of fed rats were
used in the measurements for glycogen breakdown. Silibinin was
dissolved in the perfusion ﬂuid, and its solubilisation was achieved
by the simultaneous addition of an equivalent amount of 1.0 M
NaOH.
2.4. Analytical assays
Samples of the efﬂuent perfusion ﬂuid were collected at 2-min
intervals and analysed for their metabolite content. Lactate and
pyruvate were assayed by means of standard enzymatic proce-
dures using lactate dehydrogenase [21,22]. Interference by
silibinin (absorbance at 340 nm) was excluded by running blanks.
Glucose was also assayed by means of standard enzymatic proce-
dures [23]. The oxygen concentration in the outﬂowing perfusate
was continuously monitored by employing a Teﬂon-shielded plat-
inum electrode adequately positioned in a plexiglass chamber
where the perfusate exited [24]. Metabolic rates were calculated
from the differences between the input and output and the total
ﬂow rates and were analysed in reference to the wet weights of
the livers. The hepatic contents of the adenine nucleotides weremeasured after freeze-clamping the perfused liver with liquid
nitrogen. The freeze-clamped livers were extracted with perchloric
acid. The extract was neutralised with K2CO3 and AMP, ADP, and
ATP were assayed by means of high-performance liquid
chromatography (HPLC). The HPLC system (Shimadzu, Japan) con-
sisted of a system controller (SCL-10AVP), two pumps (model
LC10ADVP), a column oven (model CTO-10AVP) and a UV–Vis
detector (model SPD-10AV). A reversed-phase C18 HRC-ODS
column (5 lm, 150  6 mm i.d., Shimadzu) protected with a
GHRC-ODS precolumn (5 lm, 10  4 mm i.d., Shimadzu) was used
with a gradient from reversed-phase 0.044 mol/L phosphate buffer
solution, pH 6.0, to 0.044 mol/L phosphate buffer solution plus
methanol (1.1), pH 7.0. In percent methanol, the gradient was
the following: at 0 min, 0%; at 2.5 min, 0.5%; at 5 min, 3%; at
7 min, 5%; at 8 min, 12%; at 10 min, 15%; at 12 min, 20%; at
20 min, 28%; and at 30 min, 0%. The temperature was kept
at 35 C, and the injection volume was 20 lL with a ﬂow rate of
0.8 mL/min. Monitoring was performed spectrophotometrically at
254 nm. Identiﬁcation of the peaks of the investigated compounds
was carried out by a comparison of their retention times with
those obtained by injecting standards under the same conditions.
The concentrations of the compounds were calculated by means
of the regression parameters obtained from the calibration curves.
The calibration curves were constructed by separating chromato-
graphically standard solutions of the compounds. Linear relation-
ships were obtained between the concentrations and the areas
under the elution curves.
2.5. Experiments with microsomes
Microsomes from livers of 24 h-fasted rats were isolated by dif-
ferential centrifugation according to Mihara and Sato [25]. Rats
were decapitated, and their livers were cut into small pieces with
scissors and suspended in cold isolation medium (4 C) containing
150 mM KCl, 0.1 mM phenylmethanesulfonyl ﬂuoride (PMSF) and
10 mM Tris–HCl (pH 7.4). After the suspension in 10 volumes of
the isolation medium, the tissue was homogenised with a Dounce
homogeniser. The homogenate was ﬁltered through gauze and
centrifuged at 2550g for 10 min in a refrigerated centrifuge. The
supernatant was again centrifuged in two steps at 7100 and
12400g for 10 min. The supernatant of the last centrifugation
was collected and centrifuged at 105,000g for 1 h. The pellet con-
taining the microsomal fraction was suspended in cold isolation
medium at a ﬁnal protein concentration of 20 mg/mL. The protein
content of the microsomes was measured according to the method
of Lowry et al. [26] using bovine serum albumin as a standard. The
glucose 6-phosphatase activity was measured in a medium con-
taining 100 mM KCl, 20 mM Tris–HCl (pH 6.5), 15 mM glucose
6-phosphate and 0.2 mg protein/mL. The D-fructose 1,6-bisphos-
phatase activity was assayed using the supernatant of the
105,000g centrifugation according to the procedure described by
Mendicino et al. [27]. The reaction mixture contained 100 mM
Tris–HCl (pH 8.0), 12 mM MgCl2, 5 mM cysteine, 1 mM D-fructose
1,6-bisphosphate and 1 mg protein/mL. Silibinin (100–300 lM)
was added to the incubation medium as a solution in dimethyl-
formamide (0.1 M). After a 20 min incubation at 37 C, the reaction
was stopped by the addition of one volume of 5% trichloroacetic
acid and phosphate release was measured according to the method
of Fiske and Subbarow [28].
2.6. Mitochondria isolation
Fed rats were decapitated, and their livers were removed
immediately and cut into small pieces. These fragments were
suspended in a medium containing 0.2 M mannitol, 75 mM su-
crose, 2.0 mM Tris-HCl (pH 7.4), 0.2 mM EGTA (ethylene glycol-bis
122 C.P. Colturato et al. / Chemico-Biological Interactions 195 (2012) 119–132(2-aminoethylether)-N,N,N0,N0-tetraacetic acid), 0.1 mM phen-
ylmethanesulfonyl ﬂuoride (PMSF), and 50 mg% (w/v) fatty acid-
free bovine serum albumin. Homogenisation was carried out in
the same medium by means of a Dounce homogeniser. After
homogenisation, the mitochondria were isolated by differential
centrifugation according Voss et al. [29] using a sucrose-mannitol
isolation medium and suspended in the same medium, which
was kept at 0–4 C.2.7. Determination of mitochondrial oxygen consumption, ADP/O ratio
and respiratory control ratio (RC)
Oxygen consumption by coupled isolated mitochondria was
measured polarographically using a Teﬂon-shielded platinum elec-
trode [24]. Intact mitochondria (2 mg protein/mL) were incubated
in the closed Oxygraph chamber in a medium containing 250 mM
mannitol, 10 mM KCl, 10 mM Tris–HCl (pH 7.4), 0.2 mM EGTA,
5 mM potassium phosphate, and 50 mg% fatty acid free bovine ser-
um albumin. Silibinin (100300 lM) was added to the incubation
medium as a solution in dimethylformamide (0.1 M). Succinate
(10 mM) and a-ketoglutarate (10 mM) were used as substrates.
ADP, at a ﬁnal concentration of 125 lM, was added at the appropri-
ate times. Rates of oxygen consumption were computed from
the slopes of the recorded tracings and expressed as
nmol min1 mg protein1. The respiratory control ratio (RC) and
the ADP/O ratio were calculated according to Chance and Williams
[30]. The protein content of the mitochondrial suspensions was
measured by means of the method described by Lowry et al. [26]
using bovine serum albumin as a standard.2.8. Pyruvate carboxylase assay
The pyruvate carboxylase activity of intact mitochondria was
assayed by measuring the incorporation of 14C from [14C]NaHCO3
into components of the tricarboxylic acid cycle. The incubation
medium contained 5 mM sodium pyruvate, 12.5 mM MgCl2,
2.5 mM potassium phosphate, 120 mM KCl, 10 mM HEPES (pH
7.5), and 3 mg protein/mL [31]. The reaction was initiated by intro-
ducing 15 mM [14C]NaHCO3 (0.25 lCi). After 10 min of incubation
at 37 C, the reaction was arrested by the addition of 0.5 volume of
2 M perchloric acid. After a 5-min expulsion of the remaining
[14C]NaHCO3, aliquots were taken for counting the acid-stable
incorporation of radioactivity. The pyruvate carboxylase of dis-
rupted mitochondria was measured using a medium able to gener-
ate steady-state concentrations of acetyl-CoA, as originally
described by Henning et al. [32]. Rat liver mitochondria, isolated
as described above, were disrupted by successive freezing and
thawing procedures using liquid nitrogen. The incubation medium
contained 3 mg protein/mL of disrupted mitochondria, 5 mM so-
dium pyruvate, 12.5 mM MgCl2, 2.5 mM potassium phosphate,
0.3 M sucrose, 1 mM EDTA (ethylenediaminetetraacetate), 5 mM
tris(hydroxymethyl) aminomethane (TRIS, pH 7.5), 0.5 mM lithium
coenzyme A, 5 mM adenosine triphosphate, 1.1 mM acetyl phos-
phate, 1 unit/mL phosphotransacetylase and 1 unit/mL citrate syn-
thase. The reaction was initiated by introducing 15 mM
[14C]NaHCO3 (0.25 lCi). After a 10 min incubation at 37 C, the
reaction was arrested by the addition of 0.5 volume of 2 M per-
chloric acid. After expulsion of the remaining [14C]NaHCO3 for
5 min, aliquots were taken for counting the acid-stable incorpora-
tion of radioactivity. The incorporated radioactivity in both incuba-
tions, intact and disrupted mitochondria, was expressed as
nmol min1 mg protein1. The scintillation solution for counting
14C was composed of toluene:Triton X-100

(1.5:0.5), 10 g/L 1.5-
diphenyloxazole with 0.4 g/L 2,2-p-phenyl-bis-5-pheny-leneoxaz-
ole. The protein content of all experiments was measured bymeans of the method described by Lowry et al. [26] using bovine
serum albumin as a standard.
2.9. Membrane-bound enzymatic activities
Rat liver mitochondria, isolated as described above, were dis-
rupted by successive freezing and thawing procedures using liquid
nitrogen and used as an enzyme source for assaying membrane-
bound enzymatic activities. NADH-oxidase and succinate-oxidase
activities were assayed polarographically using a 20 mM Tris–HCl
(pH 7.4) medium. A polarographic assay was also run with TMPD
(N,N,N0,N0-tetramethyl-p-phenylenediamine) with ascorbate as
substrates. The reactions were started by the addition of 1.0 mM
NADH, 10 mM succinate, or 0.2 mM TMPD with 5 mM ascorbate
[33].
2.10. ATPase activity
The mitochondrial ATPase activity was assayed by measuring
the phosphate release according to Pullman et al. [34]. When intact
mitochondria were used as an enzyme source, the reaction med-
ium contained 200 mM sucrose, 10 mM Tris–HCl (pH 7.4),
50 mM KCl, 0.2 mM EGTA, and, when required, 100 lM 2,4-dinitro-
phenol. For incubation with the disrupted mitochondria, the med-
ium contained 20 mM Tris–HCl (pH 7.4). The reaction was started
by the addition of 5 mM ATP, incubated for 20 min at 37 C and
stopped by the addition of ice-cold 5% trichloroacetic acid. Phos-
phate was measured as described by Fiske and Subbarow [28].
When coupled mitochondria were assayed, around 1 mg/mL of
mitochondrial protein was used as an enzyme source, and when
uncoupled or disrupted mitochondria were assayed, around
0.5 mg/mL of mitochondrial protein was used. The protein content
of all experiments was measured by the method described by
Lowry et al. [26] using bovine serum albumin as a standard.
2.11. Measurement of NADH oxidation in a cell-free system
The action of silibinin on NADH oxidation in a cell-free system
was measured according to the method of Chan et al. [35]. The
reaction mixtures contained 0.1 M Tris–HCl/1.0 mM EDTA buffer
(pH 7.4), 1.0–4.0 lM silibinin, 25 lM H2O2, 200 lM NADH, and
0.1 lM horseradish peroxidase (HRP) type VI-A. Reactions were
started by the addition of 25 lM H2O2 and the oxidation of NADH
was monitored at 340 nm using a spectrophotometer.
2.12. Treatment of data
The statistical signiﬁcance of the differences between parame-
ters obtained in the experiments was evaluated by means of Stu-
dent’s t-test or by a Newman–Keuls test after submitting the
data to variance analysis according to context. The results are dis-
cussed in the text using p values where p < 0.05 was the criterion
used for signiﬁcance.
3. Results
3.1. The effects of silibinin on gluconeogenesis from lactate and
pyruvate and oxygen consumption in the livers of fasted rats
The ﬁrst set of experiments was planned to evaluate the action
of silibinin on the gluconeogenesis pathway. Livers from rats that
were fasted 24 h were perfused with gluconeogenic substrates
and with different concentrations of silibinin. The experimental
protocol is illustrated in Fig. 2A. In this series, the substrates were
a mixture of 2.0 mM lactate plus 0.2 mM pyruvate, which is close
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Fig. 2. The effects of silibinin on the metabolic ﬂuxes from lactate and pyruvate in perfused livers isolated from fasted rats. Livers from 24 h fasted rats were perfused as
described in the Section 2. Panel A: time courses of the changes caused by 100 lM silibinin in glucose production and oxygen consumption. Lactate and pyruvate were infused
at 10–70 min and silibinin at 30–50 min, as indicated by the horizontal bars. Panel B: concentration-dependent effects of silibinin on glucose production and oxygen
consumption. The control values (zero silibinin) correspond to the rates found in the presence of lactate plus pyruvate just before the onset of silibinin infusion (30 min of
perfusion) minus the basal rates (i.e., before the onset of lactate and pyruvate infusion). Rates in the presence of lactate with pyruvate and silibinin were evaluated after
50 min of perfusion and also subtracted from the same basal rates. Each experimental point is the mean ± SEM of 3–5 experiments. Asterisks indicate a statistical signiﬁcance
in comparison to the control condition as revealed by variance analysis with post-hoc Newman–Keuls testing (⁄p < 0.05).
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2-min intervals for a total of 70 min of perfusion to measure glu-
cose release. The oxygen consumption was monitored during the
full experimental time. In the ﬁrst 10 min, only Krebs-Henseleit
buffer was infused, and the amounts of glucose released were very
small due to a low content of hepatic glycogen. Under this condi-
tion, the oxygen consumption was maintained by endogenous fatty
acid oxidation. When 2 mM lactate with 0.2 mM pyruvate were in-
fused, there was a substantial increase in both glucose production
and oxygen consumption. The infusion of 100 lM silibinin at the
30 min time period caused a progressive decrease in glucose pro-
duction and in oxygen consumption, as shown in Fig. 2A. When sil-
ibinin infusion was stopped at 50 min of perfusion, there was only
a partial recovery of the glucose production and oxygen consump-
tion and reached values well below those found before the silibinin
infusion.
Fig. 2B shows the results of four sets of experiments like those
illustrated in Fig. 2A, in which the concentration of silibinin was
varied (50, 100, 200 and 300 lM). The curves represent the
concentration-dependent effects of silibinin on glucose release
and on oxygen consumption. The control values correspond to
the average rates found in the presence of 2 mM lactate with
0.2 mM pyruvate just before the silibinin infusion and minus the
basal rates (ﬁrst 10 min of perfusion time). The values for each con-
centration of silibinin were calculated as the differences between
the control values (before silibinin infusion) and the values at the
end of the silibinin infusion period. The glucose release was inhib-
ited 89% by 300 lM silibinin, but the inhibition was already signif-
icant at the 50 lM concentration (57% inhibition). Oxygen
consumption was also signiﬁcantly inhibited; a 55% and 78% inhi-
bition was found in the presence of 50 lM and 100 lM silibinin,
respectively. At higher concentrations, the oxygen consumption
was reduced to values below the basal ones (before the gluconeo-
genic substrates infusion). At 300 lM concentration, for example,
oxygen consumption was 62% lower than the basal rates.3.2. The effects of silibinin on oxygen consumption and
gluconeogenesis from lactate or pyruvate in the livers of fasted rats
The inhibition of silibinin on the gluconeogenesis pathway from
2 mM lactate with 0.2 mM pyruvate could be explain by at least
three mechanisms: (1) a direct action on the enzyme lactate dehy-
drogenase which interconverts lactate to pyruvate; (2) a change in
the cytosolic redox potential or (3) an interference at a metabolic
step that is common for lactate and pyruvate conversion to glu-
cose. To investigate these possibilities, two series of experiments
similar to the ones illustrated in Fig. 2 were performed in which
2 mM lactate (Fig. 3) or 0.2 mM pyruvate (Fig. 4) was infused
separately.
As shown in Fig. 3, substantial amounts of glucose and pyruvate
were released by the livers after the infusion of 2.0 mM lactate. A
parallel increase in oxygen consumption was also observed. The
infusion of 100 lM silibinin promoted a progressive decrease in
both oxygen consumption and glucose production. There was, in
contrast, a small increment in pyruvate production (Fig. 3). When
the silibinin infusion was terminated, there was only a partial
recovery of the glucose production and oxygen consumption, ex-
cept for the pyruvate rates that tended to be higher than before
the silibinin infusion.
With 0.2 mM pyruvate as a substrate (Fig. 4A), the response
proﬁle was similar to those shown in Fig. 2A and Fig. 3 for glucose
and oxygen consumption, i.e., increases in both parameters with
0.2 mM pyruvate infusion and an inhibition with the 100 lM silib-
inin infusion. There was a small increment in lactate production
with 0.2 mM pyruvate infusion and a higher increment with
100 lM silibinin infusion (Fig. 4). The effects promoted by silibinin
were also partially reversed.
The concentration-dependent effect of silibinin on glucose and
lactate production and on oxygen consumption in the presence
of 0.2 mM pyruvate as substrate is shown in Fig. 4B. The data were
obtained in the same way as those presented in Fig. 2B. There were
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Fig. 3. The effects of silibinin on the metabolic ﬂuxes from lactate in perfused livers
isolated from fasted rats. Livers from 24 h fasted rats were perfused as described in
the Section 2. Lactate was infused at 10–70 min and 100 lM silibinin from 30–
50 min, as indicated by the horizontal bars. The efﬂuent perfusate was sampled in
2-min intervals and analysed for glucose and pyruvate productions. Oxygen
consumption was followed polarographically. Each experimental point is the
mean ± SEM of 3 liver perfusion experiments.
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with 50 lM and 200 lM silibinin infusion, respectively. The effects
on oxygen consumption were more pronounced; 50% inhibition
was caused by 50 lM silibinin, and at higher concentrations, the
rates of oxygen consumption decreased to values below the basal
levels. The inhibition in the presence of 100, 200 and 300 lM of sil-
ibinin was 123%, 177% and 320%, respectively. The lactate produc-
tion was increased by nearly 53% with all of the concentrations of
silibinin used.3.3. The effects of silibinin on the activities of key enzymes of the
gluconeogenic pathway
The effects of silibinin on the activities of key enzymes of gluco-
neogenesis pathway were evaluated. The enzymes examined were
glucose 6-phosphatase, D-fructose 1,6-bisphosphatase, and pyru-
vate carboxylase. As shown in Fig. 5A, silibinin had no effect on
D-fructose 1,6-bisphosphatase activity, but it caused a strong inhi-
bition on glucose 6-phosphatase activity. At the 100 lM concentra-
tion, silibinin decreased the enzyme activity by 50%, and an almost
total inhibition was observed at higher concentrations.
Silibinin was also able to inhibit the pyruvate carboxylation cat-
alysed by pyruvate carboxylase in preparations of isolated mito-
chondria (Fig. 5B). In intact mitochondria, a 50% inhibition was
found at the 175 lM silibinin concentration (data obtained byinterpolation). At the higher concentration assayed (300 lM), the
pyruvate carboxylation decreased by 75%. However, in freeze–
thaw-disrupted mitochondria, silibinin had no signiﬁcant effect
on pyruvate carboxylation.
3.4. The effects of silibinin on glycogenolysis and glycolysis
In the fed conditions, liver glycogen catabolism contributes to
the maintenance of glucose levels in circulation. When livers from
fed rats are perfused in the absence of exogenous substrate, the re-
lease of glucose, lactate, and pyruvate are derived from glycogen
catabolism, and the sum of lactate and pyruvate represents a frac-
tion of the glucose oxidised in glycolysis. Fig. 6 illustrates a typical
protocol in which silibinin was infused in these livers. In the ﬁrst
10 min of perfusion, there was a substantial release of glucose, lac-
tate, and pyruvate. The infusion of 200 lM silibinin between 10
and 40 min caused a signiﬁcant decrease in all of the metabolic
ﬂuxes. The stronger reduction in lactate production relative to
the reduction in pyruvate production indicated a decrease in the
cytosolic NADH–NAD+ redox potential, i.e., a change in the cyto-
solic potential to a more oxidised condition. After the cessation
of the silibinin infusion, there was only a partial recovery of the
oxygen consumption and lactate production toward the basal val-
ues (before the silibinin infusion). A distinct phenomenon was ob-
served in the glucose release. There was a rapid release of glucose,
reaching values 25% higher than the basal values 6 min after the
cessation of silibinin infusion. After this time, there was a progres-
sive decrease, but at the end of the experimental time period, the
values were still higher than the basal ones.
The concentration-dependent effects of silibinin on glucose re-
lease, glycolysis (the sum of the lactate and pyruvate production)
and oxygen consumption were shown in Fig. 6B. The data were cal-
culated from experiments similar to those illustrated in Fig. 6A, but
with different concentrations of silibinin (50, 100, 200 and
300 lM). The control values correspond to the rates found in the
absence of silibinin (basal rates during the ﬁrst 10 min) and the
values of other points correspond to the values obtained during
the last time point of silibinin infusion. The inhibition obtained
in each parameter was concentration-dependent. The degree of
inhibition in the presence of 300 lM of silibinin was 36%, 41%
and 21% for glucose release, glycolysis and oxygen consumption,
respectively. However, signiﬁcant inhibitions of glucose release
and oxygen consumption were already reached with 50 lM of sil-
ibinin. With 100 lM of silibinin, all parameters were signiﬁcantly
inhibited.
3.5. The effects of silibinin on parameters of energy transduction in
isolated mitochondria
To evaluate whether the metabolic changes caused by silibinin
in perfused livers could be a consequence of disturbances in the
energy metabolism, the direct effects of silibinin on several param-
eters of energy transduction were evaluated in isolated mitochon-
dria. The effects of silibinin, at a concentration range of 100–
300 lM, on respiration driven by succinate (FAD+-dependent)
and a-ketoglutarate (NAD+-dependent) are shown in Table 1. Silib-
inin inhibited the state III respiration driven by both succinate and
a-ketoglutarate. Conversely, the state IV respiration was signiﬁ-
cantly stimulated when the respiration was driven by succinate,
but not when the substrate was a-ketoglutarate. Accordingly, there
was an activation of the initial basal respiration only with succi-
nate. As a consequence of the effects of silibinin on states III and
IV of respiration, there was a progressive decrease in the respira-
tory control ratio (RC) with both substrates (Table 1).
A distinct effect caused by silibinin on the state IV and on the
basal respirations when succinate and a-ketoglutarate were
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Fig. 4. The effects of silibinin on the metabolic ﬂuxes from pyruvate in perfused livers isolated from fasted rats. Livers from 24 h fasted rats were perfused as described in the
Section 2. Panel A: time courses of the changes caused by 100 lM silibinin in glucose or lactate productions and oxygen consumption. Pyruvate was infused at 10–70 min and
silibinin at 30–50 min, as indicated by the horizontal bars. Panel B: concentration-dependent effects of silibinin on parameters measured. The control values (zero silibinin)
correspond to the rates found in the presence of pyruvate just before the onset of silibinin infusion (30 min of perfusion) minus the basal rates (i.e., before the onset of
pyruvate infusion). Rates in the presence of pyruvate and silibinin were evaluated after 50 min of perfusion and also subtracted from the same basal rates. The data points
represented the mean ± SEM of 3–5 liver perfusion experiments. Asterisks indicate a statistical signiﬁcance in comparison to the control condition as revealed by variance
analysis with post-hoc Newman–Keuls testing (⁄p < 0.05).
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the respiratory chain that were not common to the oxidation of
both substrates. A way to evaluate this possibility is the measure-
ment of the respiratory activity in freeze–thaw-disrupted
mitochondria using NADH (NADH oxidase activity), succinate
(succinate oxidase activity) or TMPD-ascorbate as substrates for
complex I, II and IV, respectively. The results are shown in Fig. 7.
Silibinin inhibited the respiration driven by succinate and by
NADH. However, the inhibition was stronger with NADH.
Whereas 300 lM silibinin promoted a 50% inhibition of respiration
driven by NADH, the respiration driven by succinate was inhib-
ited by only 15%. Silibinin did not affect the respiration driven by
TMPD with ascorbate that reduces the cytochrome c-oxidase
(Fig. 7).
The inhibition caused by silibinin on state III respiration could
be a consequence of a direct effect on the F1F0–ATP synthase com-
plex. The evaluation of the ATPase activity in three different mito-
chondrial preparations (intact-coupled, intact-uncoupled and
freeze–thaw-disrupted mitochondria) may help in the understand-
ing of the mode of action of silibinin. As shown in Fig. 8, the effects
of silibinin were dependent on its concentration and the kind of
mitochondrial preparation. In intact-coupled mitochondria, silibi-
nin stimulated ATPase activity within the concentration range of
100–300 lM.
In 2,4-dinitrophenol-uncoupled mitochondria, the ATPase
activity was not signiﬁcantly inhibited by silibinin, but aninhibition was apparent in the freeze–thaw-disrupted mitochon-
dria. At 300 lM silibinin, 27% inhibition was found.
3.6. The effects of silibinin on the adenine nucleotide contents in
perfused livers from fasted and fed rats
The observation that silibinin was active on several parameters
of energy metabolism in isolated mitochondria raised the question
of whether these effects also manifest in the intact livers and
change the energy status of the hepatocytes. To examine this pos-
sibility, the hepatic contents of ATP, ADP and AMP were measured
in livers from rats submitted to the same conditions as the exper-
iments performed in the fasted condition, in which gluconeogene-
sis was measured with 2 mM lactate and 0.2 mM pyruvate as
substrates (Fig. 2), and also in livers from fed rats as those shown
in the experimental series of Fig. 6A. In both series, the measure-
ments were made in control livers (without silibinin) and in livers
perfused with 300 lM silibinin. The results are shown in Table 2
(fasted rats) and Table 3 (fed rats). In the fasted rats, silibinin de-
creased the contents of ATP and AMP in comparison with the con-
trol values (absence of silibinin). The ADP content was not
modiﬁed. As a consequence, there was a signiﬁcant change in the
total amount of nucleotides and in the ratios of ATP/ADP and
ATP/AMP.
In the fed livers (Table 3), no signiﬁcant changes were found in
the ATP and AMP contents. Only the content of ADP was increased
AB
Fig. 5. The effects of silibinin on several enzymatic activities. Panel A: glucose 6-
phosphatase and fructose 1,6-bisphosphatase activities at various silibinin concen-
trations. Livers from fasted rats were homogenised and subjected to differential
centrifugation as described in the Section 2. The microsomal fraction was used for a
glucose 6-phosphatase assay and the supernatant was used for the fructose 1,6-
bisphosphatase assay. Panel B: pyruvate carboxylase activity of intact and disrupted
rat liver mitochondria at various silibinin concentrations. The 14CO2 incorporation
into non-volatile components of the citric acid cycle was measured as described in
the Section 2. Each data point is the mean ± SEM of 3–4 independent experiments.
⁄p < 0.05, ANOVA with post-hoc Newman–Keuls testing.
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amounts of nucleotides were not modiﬁed, but signiﬁcant de-
creases were detected in the ratios of ATP/ADP and ATP/AMP.3.7. The effects of silibinin on the catalytic oxidation of NADH
The capacity of silibinin to induce the catalytic oxidation of
NADH, which is dependent on the action of peroxidases in the
presence of H2O2, was also investigated. The results are shown in
Fig. 9. Silibinin was able to promote a strong and signiﬁcant oxida-
tion of NADH even when very low concentrations were used (1–
4 lM).4. Discussion
The results of the present study revealed that 50–300 lM of sil-
ibinin exerts pronounced effects on liver carbohydrate metabolism.
The metabolic pathways that contribute to glycaemia mainte-
nance, i.e., gluconeogenesis in the fasted condition and glycogenol-
ysis and glycolysis in the fed condition were both reduced bysilibinin corroborating the role of the liver in the antihyperglycae-
mic effect of silibinin. The mechanisms by which silibinin exerts
these actions are multiple and complex as summarised in the
illustration in Fig. 10. Silibinin has at least four different sites of
action: (a) glucose 6-phosphatase activity; (b) pyruvate carrier
(monocarboxylate carrier, which operates in the plasma and mito-
chondrial membranes); (c) mitochondrial respiratory chain at
complex I; (d) deviation of NADH supply for gluconeogenesis and
mitochondria due to a pro-oxidative action.
The inhibitory effects of silibinin on gluconeogenesis occurred
independently of the substrate that was infused. The degree of
inhibition was very similar whether the substrate was lactate,
pyruvate or a combination of both substrates. This ﬁnding ex-
cluded a change in the reaction catalysed by lactate dehydroge-
nase as the mechanism of gluconeogenesis inhibition. Glucose
production from lactate needs the lactate dehydrogenase-cata-
lysed reaction of lactate oxidation to pyruvate with NAD+. This
enzyme acts near the equilibrium of the reaction, that is, the
reaction direction is determined essentially by the NADH/NAD+
ratio. Therefore, an increase in the cytosolic NADH/NAD+ ratio is
expected to decrease the conversion of lactate to pyruvate and
then to glucose. However, the conversion of pyruvate to glucose
would not be affected. However, silibinin, at the 100 lM concen-
tration, reduced glucose production by approximately 70% irre-
spective of the substrate infused, which was lactate with
pyruvate, lactate, or pyruvate.
The possible inhibition of an enzymatic step common for both
substrates was examined, and among the key enzymes of gluco-
neogenesis, the decreased activity of two enzymes, glucose 6-
phosphatase and pyruvate carboxylase, was found. The inhibitory
action on the activity of glucose 6-phosphatase conﬁrms previous
reports from Guigas et al. [12] and Detaille et al. [13]. The authors
measured the enzyme activity in permeabilised and impermeabi-
lised microsomes and concluded that the site of silibinin action
was on the carrier unit of glucose 6-phosphatase.
Glucose 6-phosphatase catalyses the last step of gluconeogene-
sis, and its inhibition could explain only partially the reduction of
gluconeogenesis. As already demonstrated by Ishii and Bracht [36],
a strong inhibition of glucose 6-phosphatase provokes only a tran-
sitory modiﬁcation in the rates of glucose release from the liver, as
a new steady-state condition of a high intracellular glucose 6-
phosphate is reached. After the removal of inhibition, a rapid in-
crease of glucose release occurs frequently, a phenomenon that
was observed in the livers of fed rats (Fig. 6A) but not in the gluco-
neogenesis experiments (fasted rats) where the rates of glucose re-
lease remained inhibited. So, it is unlikely that the effect on glucose
6-phosphatase is the major mechanism of silibinin-induced gluco-
neogenesis inhibition.
The inhibition of pyruvate carboxylase pointed to an alternative
mechanism. It is known that pyruvate transport across the mito-
chondrial membrane is rate-limiting for pyruvate carboxylation
[37,38]. The ﬁnding that inhibition of pyruvate carboxylation was
observed in intact mitochondria, but not in disrupted mitochon-
dria, indicated that silibinin does not inhibit the catalytic activity
of pyruvate carboxylase but rather the transport of pyruvate into
the mitochondria. This effect is similar to that of a-cyano-4-
hydroxycinnamic acid, a classic inhibitor of pyruvate transport
[39] and it was also described for two other phenolic compounds,
p-coumaric acid [40] and ﬁsetin [15].
It seems highly probable that the inhibitory effect of silibinin on
pyruvate carboxylation contributed to the inhibition of gluconeo-
genesis from lactate and pyruvate. However, the effects of silibinin
on the parameters of energy metabolism indicated that it is not the
only mechanism. The strong inhibition of oxygen consumption
exerted by silibinin in the liver perfusion experiments is certainly
an important mechanism to be considered because it indicates an
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Fig. 6. The effects of silibinin on the metabolic ﬂuxes in perfused livers isolated from fed rats. Panel A: time courses of the changes caused by silibinin in glycogen catabolism
and oxygen consumption. Silibinin was infused as indicated by the horizontal bar. Samples of the efﬂuent perfusate were collected for the metabolites assays. Oxygen
consumption was followed polarographically. Panel B: The livers were perfused using different silibinin concentrations (50–300 lM). Rates of glycolysis were calculated from
lactate plus pyruvate production. The control values (zero silibinin) correspond to the basal rates found just before the onset of silibinin infusion. Rates in the presence of
silibinin were evaluated after 40 min of perfusion. Each data point represents the means of 3–5 liver perfusion experiments. Bars are standard errors of the mean. Asterisks
indicate a statistical signiﬁcance in comparison to the control condition as revealed by variance analysis with post-hoc Newman–Keuls testing (⁄p < 0.05).
Table 1
The action of silibinin on mitochondrial respiration driven by a-ketoglutarate and succinate in the presence or absence of exogenously added ADP. Mitochondria were isolated
and assayed as described in the Section 2. Incubations were performed in the presence of the substrates a-ketoglutarate and succinate, as indicated. The respiratory control ratio
(RC) and the ADP/O ratio were calculated according to the method by Chance and Williams (1955).
Substrate Silibinin (lM) Substrate respiration State III respiration State IV respiration Respiratory control ratio ADP/O ratio
(nmol O2 min-1 mg protein-1)
a-Ketoglutarate 0 4.77 ± 0.34 23.31 ± 1.71 4.97 ± 0.58 4.87 ± 0.38 2.96 ± 0.20
(n = 6) 100 4.70 ± 0.51 21.29 ± 2.34 5.67 ± 0.75 3.98 ± 0.60 2.49 ± 0.21
200 4.76 ± 0.30 15.28 ± 2.03* 5.18 ± 0.31 2.94 ± 0.35* 2.64 ± 0.18
300 4.53 ± 0.26 10.79 ± 0.91* 5.82 ± 0.93 2.04 ± 0.32* 2.28 ± 0.32
Succinate 0 14.26 ± 0.89 75.28 ± 3.91 10.66 ± 1.13 7.45 ± 0.92 2.05 ± 0.07
(n = 6) 100 16.39 ± 1.21 78.13 ± 2.87 13.18 ± 1.29 6.11 ± 0.40* 2,08 ± 0.05
200 19.17 ± 1.32* 69.53 ± 2.91 16.18 ± 1.85* 4,47 ± 0.32* 1.91 ± 0.06
300 21.48 ± 1.48* 48.27 ± 4.40* 17.60 ± 2.07* 2.79 ± 0.16* 1.84 ± 0.08
Data are the mean ± standard errors of six experiments performed by identical protocols. The statistical signiﬁcance relative to the controls is indicated by asterisks.
* p < 0.05, ANOVA with post-hoc Newman–Keuls testing.
C.P. Colturato et al. / Chemico-Biological Interactions 195 (2012) 119–132 127impairment of the mitochondrial ATP generation, which is essen-
tial for gluconeogenesis.That silibinin actually interfered with the efﬁciency of mito-
chondrial oxidative phosphorylation was clearly evident in the
Fig. 7. The effects of silibinin on several membrane-bound enzymatic activities in rat liver mitochondria. NADH-oxidase and succinate-oxidase activities and TMPD-ascorbate
oxidation were measured in freeze–thaw-disrupted mitochondria that were incubated at 37 C in reaction medium as described in the Section 2. Each data point is the
mean ± SEM of six independent experiments. ⁄p < 0.05, ANOVA with post-hoc Newman–Keuls testing.
128 C.P. Colturato et al. / Chemico-Biological Interactions 195 (2012) 119–132experiments performed in isolated mitochondria. The most pro-
nounced effect of silibinin on respiratory activity was during the
state III respiration, which combines experimental conditions that
are more similar to the conditions that exist within the cell, i.e., a
continuous requirement for the rapid regeneration of NAD+ to re-
place the electrochemical gradient expended during the phosphor-
ylation of ADP [30]. The decrease in the RC (respiratory control
ratio) in the presence of crescent concentrations of silibinin indi-
cated a decrease in the efﬁciency of ADP phosphorylation. This ac-
tion may be a consequence of the following: (a) a decrease in the
rate of electron transfer through the respiratory chain; (b) an effect
on the adenine nucleotide translocator and/or ATP synthase com-
plex; and (c) an uncoupling of oxidative phosphorylation.
A decrease in the rate of electron transfer through the respira-
tory chain was supported by the inhibition caused by silibinin on
the oxidation of NADH and succinate in disrupted mitochondria.
The ﬁndings that the inhibition was much more pronounced with
NADH as substrate in comparison with succinate, and that the oxi-
dation of TMPD-ascorbate was not modiﬁed, indicated that silibi-
nin acted on at least in two points in the respiratory chain; the
ﬁrst one was in the segment between complex II and complex III,
and the second one was in a segment preceding the transfer of
the electrons from complex I to complex III, probably at complex
I, being the action in the last step much more pronounced.
Another alternative explanation should also be considered for
the inhibition of NADH or NAD+-dependent substrate oxidation
in isolated mitochondria. Silibinin has been shown to be a strongpro-oxidative agent, i.e., it was able to oxidise NADH in vitro in
the presence of peroxidase and H2O2 (Fig. 9). This pro-oxidative ac-
tion results from the production of free-radical derivatives, such as
o-hemiquinones and o-quinones and subsequent NADH oxidation
[41–44]. It has been suggested that these reactions may also occur
in vivo with the participation of catalase, which functions as a per-
oxidase at low H2O2 concentrations [15,17,45]. In this case, a com-
petition for NADH could occur between the respiratory chain and
the silibinin metabolites, which anticipate the NADH oxidation.
This hypothesis is also consistent with the observation that an
uncoupling action was evident when succinate was the substrate
but not with a-ketoglutarate (a NAD+-dependent substrate).
This uncoupling action was indicated by the stimulation of the
respiration driven by succinate (basal and state IV respiration)
associated with a decrease in the respiratory control (RC) irrespec-
tive of the substrate (succinate or a-ketoglutarate). The stimula-
tion of the ATPase activity in intact and coupled mitochondria
also corroborated the uncoupling action of silibinin. It is known
that the ATPase activity in intact and coupled mitochondria is ret-
roactively controlled by the electrochemical proton gradient gen-
erated by proton extrusion. Any agent that causes a dissipation
of this gradient will lead to a stimulation of the ATPase activity
along with a stimulation of respiratory activity in intact mitochon-
dria [52].
It should be remembered, that in intact mitochondria, the trans-
port of adenine nucleotides is a necessary and rate-limiting step of
the ATPase activity. It was demonstrated that the activity of the
Fig. 8. The effects of silibinin on the ATPase activity of coupled, uncoupled and
disrupted mitochondria. The mitochondria were incubated at 37 C in reaction
medium as described in the Section 2. Each assay point represents the mean of six
independent experiments and the bars are the SEM. ⁄p < 0.05, ANOVA with post-hoc
Newman–Keuls testing.
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Fig. 9. The dependence of the rate of peroxidase catalysed NADH oxidation on the
silibinin concentration. The rate of NADH oxidation was determined at 340 nm in a
reaction mixture containing 0.1 M Tris–HCl/1.0 mM EDTA buffer pH 7.4, 0.1 lM
horseradish peroxidase (HRP), 200 lM NADH, 25 lM H2O2 and different silibinin
concentrations. Values represent mean ± SEM of three separate experiments.
⁄p < 0.05, ANOVA with post-hoc Newman–Keuls testing.
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uncoupled mitochondria but there was an inhibition of the enzymeTable 2
The inﬂuence of silibinin on hepatic contents of adenine nucleotides in substrate-perfus
described in the Section 2. Lactate (2.0 mM) and pyruvate (0.2 mM) were infused at 10 m
pyruvate infusion. The livers were freeze-clamped in liquid nitrogen and extracted with pe
nucleotides by HPLC. Control determinations were performed with livers that were freeze
Condition ATP ADP AMP
lmol  (g liver wet weight)1
Control (n = 5) 1.75 ± 0.06 0.86 ± 0.07 0.28 ±
Silibinin (300 lM) (n = 7) 1.27 ± 0.08* 0.92 ± 0.03 0.11 ±
Values are means ± standard errors of the mean.
* Statistically different from the corresponding control values according to Student’s t-t
Table 3
The inﬂuence of silibinin on the hepatic contents of adenine nucleotides in substrate-free p
Section 2. Silibinin (300 lM) was infused at 30 min after the start of the liver infusion. The
neutralised extracts were used for the determination of the adenine nucleotides by HPLC.
same perfusion time but without silibinin infusion.
Condition ATP ADP AMP
lmol  (g liver wet weight)1
Control (n = 3) 2.22 ± 0.04 0.81 ± 0.02 0.12 ± 0
Silibinin (300 lM) (n = 3) 1.85 ± 0.15 1.07 ± 0.04* 0.20 ± 0
Values are means ± standard errors of the mean.
* Statistically different from the corresponding control values according to Student’s t-tin disrupted mitochondria at 300 lM silibinin concentration. Un-
der the last condition, ATP has free access to the ATPase complex.
It seems plausible to suggest, thus, that silibinin exerted an addi-
tional inhibitory effect on the ATPase complex, an effect that could
contribute to a reduction of the state III respiration observed dur-
ing the oxidation of a-ketoglutarate and succinate (Table 1).
Most of the effects of silibinin observed in isolatedmitochondria
were clearly manifested in intact livers. The inhibition of oxygen
consumption observed during the infusion of silibinin in perfused
liver (Figs. 2–4 and 6) is consistent with the inhibitory action on
respiration linked to ADP phosphorylation (state III respiration).
However, the most prominent indicator of impairment of mito-
chondrial function in the intact liver was the decreased levels of
cellular ATP and the changes in the ATP/ADP and ATP/AMP ratios.
The pro-oxidative property of silibinin could also be contributing
to these metabolic disturbances. A reduction in the levels of NADH
not only could diminish the supply of reducing equivalents to the
mitochondrial respiratory chain but also to the gluconeogeniced livers of fasted rats. Livers from fasted rats were perfused in an open system as
in and 300 lM silibinin was infused 20 min after the beginning of the lactate and
rchloric acid. The neutralised extracts were used for the determination of the adenine
-clamped at the same perfusion time but without silibinin infusion.
AMP+ADP+ATP ATP/ADP ratio ATP/AMP ratio
0.03 2.90 ± 0.12 2.07 ± 0.19 6.44 ± 0.78
0.01* 2.31 ± 0.09* 1.37 ± 0.07* 13.02 ± 2.38*
est (p < 0.05).
erfused livers of fed rats. Livers were perfused in an open system as described in the
livers were freeze-clamped in liquid nitrogen and extracted with perchloric acid. The
Control determinations were performed with livers that were freeze-clamped at the
AMP + ADP + ATP ATP/ADP ratio ATP/AMP ratio
.01 3.16 ± 0.05 2.73 ± 0.11 17.71 ± 1.66
.03 3.13 ± 0.22 1.71 ± 0.08* 9.64 ± 1.34*
est (p < 0.05).
Fig. 10. Schematic representation of the effects of silibinin on metabolic pathways. The largest and grey arrows indicate the points of action of silibinin: inhibits the activity of
glucose 6-phosphatase, inhibits the pyruvate carrier (MCT monocarboxylate carrier), inhibits the respiratory chain at complex I and also acts by reducing the supply of NADH
for gluconeogenesis and mitochondria through a pro-oxidative action.
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phate dehydrogenase.
It is well known that the levels of adenine nucleotides regulate
not only the biosynthetic pathways dependent on ATP, such as glu-
coneogenesis, but they are also activators of glycogenolysis and
glycolysis. A stimulation of both processes is an expected compen-
satory result of a decrease in the mitochondrial ATP production, as
it occurs classically for drugs that alter the mitochondrial energy
efﬁciency [34,36,46,47].
Silibinin, however, did not cause such effects. In contrast, it
caused a reduction of both processes in livers from fed rats. The
inhibitory effects of silibinin on the pathways of glycolysis and gly-
cogenolysis had been already described by Detaille et al. [13]. The
mechanism for this action is not clear. The inhibition of the activity
of glucose 6-phosphatase cannot be the major mechanism, as we
have discussed above. However, an intracellular accumulation of
glucose 6-phosphate in the hepatocytes is highly probable [12].
Although we have not directly measured the intracellular concen-
tration of glucose 6-phosphate in our experiments, we have an
indicator that this phenomenon also happens, as there was anincreased release of glucose after the withdrawal of the infusion
of silibinin, upon which we have already commented.
Glucose 6-phosphate, in addition to being an intermediate of
several metabolic pathways, is also an important cell-signalling
intermediate. For instance, an increase in its levels can cause a
decrease in glycogen degradation by stimulating the activity of
glycogen synthase b and of glycogen synthase phosphatase that
leads to an increase in glycogen synthesis [48]. A repartitioning
of glucose 6-phosphate into glycogen synthesis at high cellular
glucose 6-phosphate concentrations has been reported, possibly
as a cellular response aimed at maintaining cellular glucose 6-
phosphate homeostasis [49]. We cannot discard this phenomenon
in our experiments as an explanation for the reduction of glyco-
genolysis pathway with a subsequent reduction in glucose
release.
In our liver perfusion system (Fig. 6), the theoretically accumu-
lated glucose 6-phosphate was not completely released in free glu-
cose when the silibinin infusion was stopped, suggesting that it
was consumed in another metabolic pathways. A stimulation of
the pentose-phosphate pathway could be a possible way to
C.P. Colturato et al. / Chemico-Biological Interactions 195 (2012) 119–132 131regenerate the NADPH that may be necessary for silibinin metabol-
isation and also to counteract the pro-oxidative action of silibinin.
The possibility of a direct action of silibinin on the activity of
other enzymes involved in glycogen catabolism and glycolysis
can also be considered, as was reported for other structurally-re-
lated phenolic compounds [50,51]. The inhibition of pyruvate ki-
nase by silibinin, with a resultant accumulation of
phosphoenolpyruvate inside the cell, was reported by Detaille
et al. [13].
Our data allow the conclusion that the inhibitory effects of sil-
ibinin on gluconeogenesis in the fasted condition and on glycogen
metabolism in the fed condition may contribute to the antihyper-
glycaemic action of silibinin, corroborating, thus, its clinical utilisa-
tion for diabetes treatment. However, we have also demonstrated
that the mechanisms of these actions are complex, including a
pro-oxidative effect and an impairment of the mitochondrial en-
ergy transduction. Impairment of ATP production and the cellular
redox state could lead, potentially at least, to metabolic disorders,
a ﬁnding that should be considered in its therapeutic usage.
The comparison of the effects of silibinin revealed in the present
work and those reported for quercetin and ﬁsetin, under the same
experimental conditions, allow some considerations about the
relationship between their structures and biological activities.
The inhibition of gluconeogenesis in the fasted condition and the
inhibition of glycolysis in the fed condition are effects shared by
all of them [14,15]. Quercetin activated glycogenolysis at concen-
trations near 300 lM [16], but an inhibitory effect was caused by
ﬁsetin [15] and silibinin. The most prominent differences between
the three compounds in the perfused rat liver were their effects on
oxygen consumption in fed rats. Whereas silibinin caused an inhi-
bition of oxygen consumption, quercetin, at similar concentration,
induced a stimulation of oxygen consumption [16] and ﬁsetin did
not induce a signiﬁcant effect [15]. Furthermore, silibinin was the
unique compound that signiﬁcantly reduced the adenine nucleo-
tide contents in the liver.
The actions on mitochondria were also very similar for all com-
pounds. They acted as uncouplers of oxidative phosphorylation
and inhibitors of the respiratory chain and as inhibitors of ATPase
activity. There was also a similarity in their effects on key enzymes
of gluconeogenesis [14–16,52].
It has not yet been established exactly what region of the ﬂavo-
noid molecules is responsible for their different and numerous bio-
logical effects. There are some well-established correlations for the
antioxidant capacity: (a) the presence of 2,3 unsaturation in conju-
gation with the 4-oxo group in ring C; (b) the dihydroxylated
B-ring (catechol), which allows prompt hydrogen donation (elec-
trons); (c) a high degree of hydroxylation; (d) the presence of the
3- and 5-hydroxyls [53,54]. Quercetin has all the related character-
istics (a, b, c and d) and ﬁsetin has the features listed in items a, b
and c. Silibinin possesses only the last two related characteristics
(items c and d) and thus could have a lower antioxidative property.
It should be remembered that silibinin also possesses an additional
chemical group (a dimer of phenylpropanoid, Fig. 1).
Our results indicated that these structural differences did not
exert a great inﬂuence on the metabolic effects of silibinin in the
liver when compared with the effects of quercetin and ﬁsetin
[14–17,52]. However, silibinin exerted some distinct effects such
as the inhibitory effect on oxygen consumption in the livers of
fed rats and a decrease in the ratio of adenine nucleotides in the
livers of fed and fasted rats; this could be attributed to some of
these structural differences, i.e., the absence of the 2,3 unsatura-
tion in conjugation with the 4-oxo group, or the absence of cate-
chol-ring or the presence of the phenylpropanoid dimer. Thus, it
seems that regarding its effects on energy metabolism, silibinin ex-
erts additional undesirable effects when compared with quercetin
and ﬁsetin.Finally, we relate the concentration range of silibinin used in
the present study with therapeutic doses commonly adminis-
trated. At therapeutic doses from 100 to 300 mg, the plasma con-
centration reaches levels between 200 and 1400 lg/L [55,56]. It
is known also that the portal concentration can achieve levels
much higher than in the systemic circulation and also that the bile
concentration can reach values 100 times higher than the plasma
[57,58]. Thus, it is highly probable that the portal concentrations
reach values that are similar to the range of silibinin used in this
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